Enzishil 160mg Tablets: An Advanced Treatment for Prostate Cancer

Product Introduction

Enzishil 160mg Tablet is an oral anticancer agent containing the active ingredient Enzalutamide $160\text{ mg}$. This medication is a potent, single-dose formulation of the Androgen Receptor ($\text{AR}$) Inhibitor and represents the recommended full daily dose for the treatment of advanced prostate cancer. Enzishil 160mg effectively blocks the androgen signaling pathway, crucial for managing cancer that has become resistant to initial hormone therapies.

Uses of Enzishil 160mg Tablets

Enzishil 160mg Tablet is indicated for the treatment of:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): Prostate cancer that has spread to other parts of the body and is progressing despite medical or surgical castration.
• Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC): For men whose cancer has not spread but is progressing based on rising $\text{PSA}$ levels ($\text{PSA}$ Doubling Time $\le 10$ months).
• Metastatic Castration-Sensitive Prostate Cancer (mCSPC): Used in combination with Androgen Deprivation Therapy ($\text{ADT}$) for men with metastatic, hormone-sensitive disease.

Benefits of Enzishil 160mg Tablets

The $160\text{ mg}$ single-tablet formulation offers significant benefits:

• Optimal Compliance: As the full recommended daily dose in a single tablet, it drastically improves patient adherence by reducing the pill count compared to multi-capsule regimens ($\text{e.g.,}$ four $40\text{ mg}$ capsules).
• Triple-Action AR Inhibition: It is a selective anti-androgen that provides competitive inhibition of androgen binding, blocks $\text{AR}$ nuclear translocation, and impairs $\text{AR}$ binding to $\text{DNA}$, effectively halting androgen-driven cancer growth.
• Proven Efficacy: Backed by robust clinical data confirming its effectiveness in extending overall survival and delaying disease progression in various advanced prostate cancer settings.

Side Effects of Enzishil 160mg Tablets

Side effects are predominantly $\text{CNS}$ and musculoskeletal in nature.

• Common Side Effects: Fatigue/asthenia, musculoskeletal pain (including back pain and joint pain), hot flashes, diarrhea, headache, hypertension, and peripheral edema.
• Serious Side Effects (Requires prompt reporting): Seizures (occurs rarely, but severely; discontinue permanently if a seizure occurs), Posterior Reversible Encephalopathy Syndrome ($\text{PRES}$) (a rare neurological disorder), Ischemic Heart Disease (e.g., heart attack, stroke), and falls/non-pathologic fractures.

How to Use Enzishil 160mg Tablets

• Dosage: The recommended dose of Enzalutamide is $160\text{ mg}$ administered orally once daily (one $160\text{ mg}$ tablet).
• Administration: Enzishil 160mg Tablets should be swallowed whole with water. They must not be cut, crushed, chewed, or dissolved.
• Food: The tablet can be taken with or without food as food does not significantly affect the drug’s overall absorption.
• Timing: It should be taken at approximately the same time each day for consistency.

How Enzishil 160mg Tablets Works?

Enzishil 160mg Tablet contains Enzalutamide, a potent competitive inhibitor of the Androgen Receptor ($\text{AR}$). Its anti-cancer activity results from a triple blockade of the $\text{AR}$ signaling pathway:

1. Blocks Ligand Binding: Prevents androgens from binding to the $\text{AR}$.
2. Blocks Nuclear Translocation: Inhibits the movement of the activated $\text{AR}$ into the cell nucleus.
3. Blocks $\text{DNA}$ Binding: Impairs the $\text{AR}$ complex’s ability to bind to $\text{DNA}$ and initiate the gene transcription necessary for cancer cell growth. This comprehensive blockade is highly effective in treating prostate cancer that is typically reliant on $\text{AR}$ signaling.

• Seizure Risk: Permanently discontinue the drug if a seizure occurs. Counsel patients to avoid activities where sudden loss of consciousness could cause serious harm.
• Women and Pregnancy:
• Enzishil is strictly contraindicated in women, particularly those who are pregnant or may become pregnant, due to the risk of fetal harm.
• Contraception: Male patients with female partners of reproductive potential must use effective contraception during treatment and for three months after the last dose.
• Drug Interactions (CYP Induction): Enzalutamide is a potent $\text{CYP}3\text{A}4$ inducer. It can drastically reduce the concentration and efficacy of many co-administered drugs (e.g., certain statins, opioids, $\text{warfarin}$).

What if You Forget to Take Enzishil 160mg Tablets?

If a patient misses a dose, they should take the prescribed dose as soon as they remember on the same day. If they only remember on the next day, they must skip the missed dose and take the next dose at the regular time. Patients must not take more than $160\text{ mg}$ in one day.

Quick Tips

• Single Tablet Simplicity: Advise patients to take just the single $160\text{ mg}$ tablet once daily for their full dose.
• $\text{CNS}$ Monitoring: Stress the need for immediate reporting of any new symptoms like confusion, dizziness, or rapidly worsening headache.
• Ischemic Risk: Monitor and manage cardiovascular risk factors (hypertension, diabetes, dyslipidemia) optimally throughout treatment.

FAQs

Q1: What are the key benefits of stocking the 160mg strength for bulk buyers compared to lower strengths?

A: The $160\text{ mg}$ tablet is the single-pill presentation of the full recommended daily dose (often composed of four $40\text{ mg}$ or two $80\text{ mg}$ units). This single-tablet convenience is highly sought after as it simplifies dispensing, minimizes labeling errors, and optimizes patient adherence in all clinical settings.

Q2: Is a dosage adjustment of Enzishil 160mg Tablet required for patients with liver or kidney impairment?

A: No initial dosage adjustment is typically necessary for patients with mild to severe hepatic impairment ($\text{Child-Pugh A-C}$) or mild to moderate renal impairment. However, caution and close monitoring are required, especially for severe liver impairment, as safety data are limited.

Q3: How does UnnatiPharmax ensure the quality and regulatory compliance of Enzishil 160mg Tablet for global export?

A: We guarantee a pharmaceutical-grade product manufactured under strict $\text{GMP}$ guidelines. All bulk shipments include a Certificate of Analysis ($\text{CoA}$) and compliant packaging that maintains stability (Store below 30∘C) for all international customs and regulatory requirements.

Q4: What is the most critical interaction risk associated with Enzishil 160mg Tablet for co-administered drugs?

A: Enzalutamide is a potent $\text{CYP}3\text{A}4$ inducer. This can significantly reduce the plasma concentration of many co-administered drugs (including certain anti-epileptics, opioids, and $\text{warfarin}$), leading to potential therapeutic failure or $\text{sub}$-therapeutic drug levels.

Q5: Are there specific patient groups that are generally excluded from Enzalutamide treatment? A: Patients with recent or uncontrolled cardiovascular events (e.g., severe or unstable angina, recent stroke/$\text{MI}$) and those with a history of seizures or significant $\text{CNS}$ risk factors were generally excluded from pivotal trials and should be managed with extreme caution.

Q6: Does the Enzishil 160mg Tablet need to be taken on an empty stomach?

A: No. Unlike Abiraterone, Enzishil ($\text{Enzalutamide}$) can be taken with or without food, as the overall drug exposure is not significantly altered by meal consumption. This adds to the convenience of the single-tablet regimen.

A Note to Our Bulk Buyers:

UnnatiPharmax guarantees a secure supply of pharmaceutical-grade Enzishil 160mg Tablets. We assure an efficient supply chain with compliant international shipping to our valued partners in Australia, Germany, Singapore, the UK, the US, and the Philippines.

References:-

• U.S. Food and Drug Administration (FDA) – Drug Label (Detailed Prescribing Info):
  • https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213674s002lbl.pdf
  • (Full Prescribing Information for Xtandi, showing the 160mg daily dosage for CRPC and mCSPC)
• NIH – PubMed Central (PMC) – Pharmacokinetic Study:
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC4580721/
  • (Clinical Pharmacokinetic Studies of Enzalutamide, focusing on the 160 mg daily dose)
• NIH – National Cancer Institute (NCI) – Survival Study:
  • https://www.cancer.gov/types/prostate/research/enzalutamide-metastatic
  • (Summary of the PREVAIL trial showing Enzalutamide improves survival in metastatic prostate cancer)
• ResearchGate – Efficacy and Safety Meta-Analysis (Systematic Review):
  • https://www.researchgate.net/publication/326181033_Efficacy_and_Safety_of_Enzalutamide_in_Metastatic_Prostate_Cancer_Patients_A_Systematic_Review_and_Meta-Analysis
  • (Systematic review of Enzalutamide efficacy and safety in mPCa patients)
• NIH – PubMed Central (PMC) – Review Article:
  • https://pmc.ncbi.nlm.nih.gov/articles/PMC4407758/
  • (Review of Enzalutamide for patients with metastatic castration-resistant prostate cancer)